Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

@article{Silberstein2010FeasibilityAE,
  title={Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.},
  author={Jonathan L. Silberstein and Frederick Millard and Reza Mehrazin and Ryan P. Kopp and Wassim M Bazzi and Christopher J Diblasio and Anthony Patterson and Tracy Morris Downs and Furhan Yunus and Christopher J. Kane and Ithaar H Derweesh},
  journal={BJU international},
  year={2010},
  volume={106 9},
  pages={1270-6}
}
OBJECTIVE To investigate efficacy of neoadjuvant tyrosine kinase-inhibitor therapy (TKI) before imperative nephron-sparing surgery (NSS), as NSS in patients with large locally advanced or centrally located tumours can be challenging, and TKI therapy might result in a reduction of primary tumour burden and increase the feasibility of NSS. PATIENTS AND METHODS This was a multicentre retrospective review and prospective pilot study of patients undergoing neoadjuvant sunitinib before planned NSS… CONTINUE READING